Standard BioTools Q2 Revenue $20.1M; Adj. EBITDA Improves 84%
Standard BioTools Inc. announced its second quarter 2026 financial results, reporting revenue of $20.1 million, a 7.6% decrease year-over-year. Despite the revenue decline, the company achieved an 84% improvement in adjusted EBITDA, reaching a loss of $2.5 million, and a 1% improvement in operating loss, driven by continued cost discipline. The merger with Treeline Biosciences is progressing as planned, with a stockholder vote and closing expected before year-end 2026, leading the company to withdraw its full-year 2026 revenue outlook.
Key Highlights
- Merger with Treeline Biosciences is progressing, with stockholder vote and closing anticipated before year-end 2026.
- Second quarter 2026 revenue was $20.1 million, a 7.6% decrease year-over-year.
- Adjusted EBITDA improved by 84% year-over-year to a loss of $2.5 million.
- Operating loss improved by 1% year-over-year to $(25.4) million.
- Net loss from continuing operations was $(21.5) million, compared to $(17.7) million in Q2 2025.
- Gross margin increased to 52.4% from 48.8% in the prior year quarter.
- Cash, cash equivalents, and investments totaled $541.1 million as of June 30, 2026.
- The company withdrew its full-year 2026 revenue outlook due to the pending merger.
Price Impact
More from LAB
Standard BioTools to Merge with Treeline; SomaScan Divestment Complete
Standard BioTools Q2 Revenue $20.1M; Adjusted EBITDA -$2.5M; Treeline Merger On Track
Standard BioTools Sells Mass Cytometry Business; Gets $30M Illumina Buyout